Application of Eryngiolide A in medicines curing rarefaction of bone caused by lack of antiestrogen

Abstract

The invention discloses a new use of Eryngiolide A for curing rarefaction of bone. The rarefaction of bone is an important disease damaging human health, with aging of population, rarefaction of bone patients gradually increase, the rarefaction of bone causes huge burden on society, medical treatment and economy. Although relative experts and scholars at home and abroad attach great importance to prevent and cure the rarefaction of bone, the rarefaction of bone still lacks effective curing medicines. The fact that the Eryngiolide A has evident rarefaction of bone resisting function is discovered through in vivo test. Experiment results show that the Eryngiolide A can inhibit strengthening of bone conversion rate caused by ovariectomizing, reduce bone destruction, meanwhile can improve blood calcium concentration, and is benefit for deposition of bones. The Eryngiolide A has therapeutic effect on the deposition of rarefaction of bone caused by lack of the antiestrogen, and has no estrogen side effect.

Description

technical field [0001] The invention relates to the field of drugs related to anti-osteoporosis, in particular to the new application of Eryngiolide A for preventing and treating osteoporosis. Background technique [0002] Osteoporosis is a systemic, metabolic bone disease characterized by reduction and loss of bone mass, bone fragility and increased risk of fracture. With the aging of the population, the incidence of osteoporosis has also increased rapidly, and it has become an important disease that endangers human health and has brought a huge social and economic burden to the world. Although relevant experts and scholars at home and abroad attach great importance to the prevention and treatment of this disease, there is still a lack of effective therapeutic drugs for this disease. [0003] At present, commonly used clinical drugs for the prevention and treatment of osteoporosis include estrogen replacement drugs, bisphosphonates, selective estrogen receptor modulators, ...

AI Technical Summary

Problems solved by technology

Although bisphosphonates are effective, they can cause serious adverse reactions such as osteonecrosis of the jaw, musculoskeletal pain, and renal failure; although hormone replacement therapy is an important method to prevent and treat postmenopausal osteoporosis, long-term use can cause breast cancer , endometrial cancer potential risk and increased risk of thrombosis; selective estrogen receptor modulators can significantly increase thrombotic events

Other drugs are either expensive or have uncertain long-term curative effects, which are not ideal

Images